While post-myocardial infarct patients with frequent ventricular premature contractions or nonsustained ventricular tachycardia (NSVT) are at an increased risk of sudden arrhythmic death, the empirical use of antiarrhythmic agents for such patients is no longer justified after the results of the Cardiac Arrhythmia Suppression Trial. A series of major breakthroughs in the design and clinical application of the implantable cardioverter defibrillator (ICD) have taken place over the past two decades since its invention by M Mirowski. Although there is a general consensus for the effectiveness of the ICD therapy in aborting sudden arrhythmic death, it is unknown whether the use of the ICD therapy results in prolonged survival. Three randomized clinical trials directed to the survivors of cardiac arrest due to ventricular tachycardia (VT) or ventricular fibrillation (VF) are currently in progress, comparing the ICD therapy with drug therapy (amiodarone, beta blockers, and sotalol). Already over seventeen hundred patients have been randomized and followed in these three clinical trials. All three trials continue currently indicating no emergence of statistically significant differences in total mortality between the two therapy groups. Prophylactic application of the ICD has been studied in the MADIT (Multicenter Automatic Defibrillator Implantation Trial)-the first randomized clinical trial dealing with implantable defibrillators.
Introduction
In the United States (population about 250 million) heart disease remains a health problem of epidemic proportion, in 1994 causing 734,000 cardiac deaths despite the remarkable decline in an age-adjusted cardiac death rate achieved since the middle of 1960's. [1] [2] [3] In the same year in the United States, human immunodeficiency (HIV) infection caused 42,000 deaths.2 About 300,000 of the cardiac deaths occur suddenly, most the result of ventricular fibrillation (VF) or ventricular tachycardia (VT). 4 Furthermore, 100,000-150,000 people annually are successfully resuscitated. Most of the patients dying from or surviving life-threatening ventricular tachyarrhyth mias suffer from significant structural heart disease coronary artery disease comprising about 80% of the structural heart diseases in the United States. Significant advances have taken place during the past decade in elucidating electrophysiological mechanisms for the initiation and maintenance of ventricular fibrillation. 5, 6 In this article we will review the recent progress achieved in the prevention and therapy of sudden cardiac arrhyth mic deaths, with an emphasis on two dominant therapeutic modalities-implantable cardioverter defibrillator (ICD) and amiodarone.
Previous Studies for Prevention of Sudden Cardiac Death

CAPS and CAST
In patients surviving acute myocardial infarction, cardiac pump failure and ventricular arrhythmias in cluding ventricular premature contractions (VPC's) and ventricular tachycardia (VT) are independent predictors of one year cardiac mortality, mostly in the form of sudden cardiac death.7 One year cardiac mortality was a function of the VPC's detected in predischarge ambulatory ECG recordings independent from the effect of left ventricular failure.7 This relationship along with the avail ability of several antiarrhythmics gave birth to the VPC hypothesis: Does suppression of the post-MI VPC's with antiarrhythmics lead to a reduction in sudden cardiac death?
The Cardiac Arrhythmia Pilot Study (CAPS) and the Cardiac Arrhythmia Suppression Trial (CAST), both supported by the National Institute of Health (NIH), unexpectedly revealed that the use of flecainide, encainide or moricizine in the post-MI patients with frequent VPC's and non-sustained VT resulted in increased rates of both overall and sudden cardiac death rates in spite of the continued suppression of the VPC's.8-15 Therefore, "routine" prophylactic suppression of post -MI VPC's or relatively asymptomatic nonsustained VT with anti arrhythmics is no longer recommended. In addition, the therapy with these antiarrhythmic drugs in the post infarct patients resulted in increased death rates in both sudden arrhythmic and nonsudden nonarrhythmic deaths.9-15 Thus, these drugs exerted not only serious proarrhythmic side effects but also serious negative inotropic side effects. Trial) and EMIAT (European Myocardial Infarction Amiodarone Trial). In the former, which is similar in design to the CAST trials, amiodarone therapy resulted in a 40-50% reduction in arrhythmic death but in no reduction in nonarrhythmic death rate. Severe amiodarone toxicity was rare. Another Class III agent having a weak beta-blocking effect, d,l-sotalol, was recently shown to be superior to other antiarrhythmias (excluding amiodarone) in the prevention of death and recurrent ventricular arrhythmias.27 Clinical applicability of the result of this study, however, remains uncertain.
Coronary artery bypass graft surgery
In the survivors of cardiac arrest having operable coronary stenoses, successful coronary revascularization abolished inducible ventricular arrhythmias in those patients whose cardiac arrests were due to VF but not in those due to VT, hinting myocardial ischemia played a crucial role in the VF patients.28 Thus, those survivors of cardiac arrest due to VF having operable coronary stenoses should undergo coronary artery bypass surgery which may have to be followed by either implantation of an ICD or drug therapy including amiodarone or a beta blocker.
Implantable Cardioverter Defibrillators (ICD's) Development of ICD's
Since the first clinical implantation of an ICD in 1980 by Mirowski and his associates, we have witnessed a series of major breakthroughs in the design and clinical application of the ICD (see Fig 1) the prevailing but unfounded concept that the benefit of ICD's in saving patients from sudden arrhythmic death was so striking that withholding their use in such patients would be unethical.40,41 While there is a general consensus for the utility of ICD therapy in aborting sudden cardiac death (see Fig 1 and 2) , unexpected trends were revealed in recent retrospective case-controlled studies .40-43 For instance, in a retrospective study on sixty consecutive patients implanted with ICD's and 120 medically treated patients, sudden deaths were fewer in the ICD recipients Akiyama T: Ventricular Arrhythmias and Sudden Cardiac Death than in control.42 Although actuarial survival was higher in the ICD recipients for the first three years than in the medical group, two survival curves converged beyond the first three years.42 This convergence of the overall mortality rates most likely resulted from progressive deterioration in the underlying structural heart disease.
Randomized prospective clinical trials comparing ICD and druggs
Three randomized clinical trials directed to the sur vivors of VT or VF are currently in progress in three countries, the CASH (Cardiac Arrest Study Hamburg), CIDS (Canadian Implantable Defibrillator Study) and AVID (Antiarrhythmics vs Implantable Defibril lator).44-47 The Canadian and American AVID studies are similarly designed to determine whether survival of patients with life-threatening ventricular arrhythmias is better with an ICD or drug therapy (amiodarone in the CIDS and amiodarone and d,l-sotalol in the AVID).45-47 At this writing, well over seventeen hundred patients have been randomized and followed in these three clinical trials. All of the three trials continue cur rently, indicating no emergence of statistically significant differences in total mortality between the ICD and drug therapy groups.
Prophylactic use of implantable defibrillators has been also studied in one randomized clinical trial, MADIT (Multicenter Automatic Defibrillator Implantation Trial)-the first randomized clinical study dealing with implantable defibrillators. 48 This study was started in 1990, had enrolled post-transmural infarct patients having documented nonssustained VT, LV dysfunction (LVEF 35% or lower), and inducible and nonsuppressible nonsustained VT in electrophysiological testings. 48 The patients satisfying these criteria had been randomized to implantable cardioverter defibrillator therapy (95 patients) or to conventional medical therapy (101 patients). At one month after randomization, amiodarone was prescribed in 74% of the conventional therapy and 2% of the ICD group. The trial was terminated in March 1996 because of an emergence of a highly statistically significant benefit of the ICD therapy over the con ventional therapy (15 deaths in the ICD group and 39 deaths in the conventional group, p=0.009). This beneficial effect existed in both thoracotomy ICD and transvenous ICD patients. In addition, 60% of the ICD group patients received ICD discharges within two years after enrollment. Many of these patients are considered to have died without their implanted ICD's. with further improvement in the therapy directed at the underlying structural heart disease.
Conclusion
